| Autor: |
Alqurashi A; Independent Researcher, Makkah 4192, Saudi Arabia., Sindy EA; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Dosh H; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Khayat SZ; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Alqarna LM; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Sodagar WM; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Samannodi M; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Alwafi H; Collage of Medicine, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Salawati E; Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Saudi Arabia., Almatrafi MA; Department of Pediatrics, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Ekram R; School of Public Health and Health Informatics, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Bagadood RM; Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Alsafi R; Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24382, Saudi Arabia., Assaggaf HM; Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 24382, Saudi Arabia. |
| Abstrakt: |
Background: Soon after the COVID-19 pandemic was declared, a pharmaceutical company expressed rapid interest in developing a safe and effective vaccine candidate to contain the spread of SARS-CoV-2 infections. The FDA approved the Pfizer-BioNTech, AstraZeneca, Moderna, and Janssen vaccines. Here, we investigated the attitude and acceptance of using different generic types of COVID-19 vaccines in Saudi Arabia. Methods: This study is a cross-sectional study using an online survey conducted in Saudi Arabia from the 19th of October to the 6th of December 2021. The questionnaire was distributed using social media platforms such as Twitter, WhatsApp, and Facebook. The inclusion criteria to participate in this study were adults who live in Saudi Arabia (Saudis or non-Saudis) and had two doses of COVID-19 vaccinations. Result: 3486 participants were included in this study, and 67.5% of the participants had side effects after the first dose. Similarly, 66.7% of the study participants had side effects after administering the second dose. Our data showed that most participants were unsure if the heterologous COVID-19 vaccination could cause severe side effects. In addition, 47.6% of the participants refused to receive a different generic type of COVID-19 vaccine due to fear of health problems. However, most participants obtained information regarding COVID-19 vaccination from the Saudi Ministry of Health. Conclusions: We found a low level of acceptance for receiving different generic types of vaccines if the participants had a choice. Therefore, plans should focus on increasing the acceptance level among the Saudi population through official platforms such as the Saudi Ministry of Health and private clinics. |
